Shifts in Cohort Eligibility With Deimplementation of Race-specific Guidance for Hepatocellular Carcinoma Surveillance.

ABSTRACT:

Background and aims

Clinical guidance for hepatocellular carcinoma (HCC) surveillance for patients with chronic hepatitis B virus (HBV) recently removed race from eligibility criteria, and replaced it with country of origin from a HBV-endemic country and PAGE-B score greater than 10. This study sought to determine adherence to prior race-based guidance and how demographic cohort eligibility would shift using new criteria.

Methods

This was a retrospective cohort study of patients with chronic HBV with an outpatient office visit at our institution from June 1, 2022, to June 1, 2023. Patients with a personal history of cirrhosis, HCC, or comorbid viral hepatitis were excluded. HCC surveillance practices were extracted using chart review. PAGE-B scores were calculated utilizing

SUBMITTER: Macedo B 

PROVIDER: S-EPMC12539228 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature